Davalintide is an Amylin-mimetic peptide known for its high potency and extended action. It is a highly effective agonist of the amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM), and calcitonin gene-related peptide receptor [CGRP receptor] (IC50 = 3.1 nM). Davalintide demonstrates greater efficacy than Amylin in cyclic adenosine monophosphate production through calcitonin receptor activation (EC50 = 1.4 nM). It modulates blood glucose and body weight through mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide is utilized in research related to anti-obesity and antidiabetic treatments.

Davalintide, administered intraperitoneally at doses of 1.09-1087 μg/kg in mice and 5 μg/kg in rats, single dose, effectively suppresses food intake in fasting mice and overfed rats with superior efficacy and duration compared to Amylin. Its administration at 1-100 μg/kg intraperitoneally in rats does not affect spontaneous activity while reducing food consumption, indicating that its appetite-suppressing effects are not mediated by adverse reactions such as nausea or aversion. When administered subcutaneously at 1-100 μg/kg daily for 8 weeks, Davalintide significantly reduces food intake and body weight in rats, primarily through fat reduction while maintaining lean mass, offering metabolic benefits beyond simple caloric restriction. At a subcutaneous dose of 10 μg/kg daily for 4 weeks, it markedly decreases total caloric intake, reduces preference for high-fat and palatable foods, and encourages selection of standard feed. A single intraperitoneal dose of 10 μg/kg affects the hindbrain to durably activate downstream neural pathways in rats, contributing to obesity inhibition. Finally, at a subcutaneous dose of 10 μg/kg, Davalintide specifically inhibits the rise in glucagon induced by arginine stimulation in anesthetized rats.